Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.51 |
| ▸ | TP53 | P04637 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390896 | 0.76 | GPR119 (0.62) | GPR119TP53KDM4ENPC1RAB9A | |
| SCHEMBL5652107 | 0.76 | GPR119 (0.55) | GPR119NPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL6015448 | 0.76 | GPR119 (0.53) | GPR119NPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL390871 | 0.75 | GPR119 (0.62) | GPR119TP53KDM4ENPC1RAB9A | |
| SCHEMBL12914919 | 0.72 | TP53 (0.74) | GPR119TP53KDM4ENPC1RAB9A | |
| SCHEMBL12835886 | 0.71 | GPR119 (0.66) | GPR119TP53KDM4ENPC1RAB9A | |
| SCHEMBL12903920 | 0.71 | GPR119 (0.66) | GPR119TP53KDM4ENPC1RAB9A | |
| SCHEMBL391084 | 0.71 | GPR119 (0.66) | GPR119TP53KDM4ENPC1RAB9A | |
| SCHEMBL1245463 | 0.71 | GPR119 (0.66) | GPR119TP53KDM4ENPC1RAB9A | |
| SCHEMBL5653149 | 0.70 | GPR119 (0.56) | GPR119TP53LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICLAS, INC. (US) | 2007-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | GPR119 36/4885TP53 4398/4885KDM4E 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.